Finance entity
earnings is the sole category represented across all 2 tracked stories. Collegium Pharmaceutical is most often covered alongside GSK, which appears in 1 of these 2 stories. Across a 165-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window.
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 2 tracked stories. Collegium Pharmaceutical is most often covered alongside GSK, which appears in 1 of these 2 stories. Across a 165-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Collegium Pharmaceutical appears in 2 tracked Finance stories published from February 26, 2026 through August 9, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 3492 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Collegium Pharmaceutical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
